Cargando…
Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies
Myelodysplastic neoplasms (MDS) are a collection of hematopoietic disorders with widely variable prognoses and treatment options. Accurate pathologic diagnoses present challenges because of interobserver variability in interpreting morphology and quantifying dysplasia. We compared local clinical sit...
Autores principales: | Gorak, Edward J., Otterstatter, Michael, Al Baghdadi, Tareq, Gillis, Nancy, Foran, James M., Liu, Jane Jijun, Bejar, Rafael, Gore, Steven D., Kroft, Steven H., Harrington, Alexandra, Saber, Wael, Starczynowski, Daniel, Rollison, Dana E., Zhang, Ling, Moscinski, Lynn, Wilson, Steffanie, Thompson, Jason, Borchert, Christine, Sherman, Seth, Hebert, Donnie, Walker, Mary Ellen, Padron, Eric, DeZern, Amy E., Sekeres, Mikkael A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582385/ https://www.ncbi.nlm.nih.gov/pubmed/37552083 http://dx.doi.org/10.1182/bloodadvances.2023010061 |
Ejemplares similares
-
Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions
por: DeZern, Amy E., et al.
Publicado: (2023) -
Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study
por: Abel, Gregory A., et al.
Publicado: (2023) -
A geno-clinical decision model for the diagnosis of myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2021) -
COVID-19 Outcomes Among Participants in the NHLBI Myelodysplastic Syndromes (MDS) Natural History Study
por: Padron, Eric, et al.
Publicado: (2021) -
Momelotinib is a highly potent inhibitor of FLT3-mutant AML
por: Azhar, Mohammad, et al.
Publicado: (2022)